RedHill Biopharma Rises After Positive FDA Feedback on Crohn's Drug

Dow Jones

Jul 22

By Nicholas G. Miller

American depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease.

The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year.

The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041.

Write to Nicholas G. Miller at nicholas.miller@wsj.com

(END) Dow Jones Newswires

July 21, 2025 12:20 ET (16:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2553405263"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553405263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553405263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553405263","market":"us","top_or_hot":-1,"title":"RedHill Biopharma Rises After Positive FDA Feedback on Crohn's Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease. \n</p>\n<p>\n  The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year. \n</p>\n<p>\n  The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2025 12:20 ET (16:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma Rises After Positive FDA Feedback on Crohn's Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma Rises After Positive FDA Feedback on Crohn's Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-22 00:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Nicholas G. <a href=\"https://laohu8.com/S/MLR\">Miller</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease. \n</p>\n<p>\n  The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year. \n</p>\n<p>\n  The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2025 12:20 ET (16:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDHL","symbol_name":"Redhill Biopharma Ltd","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553405263","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553405263","pubTimestamp":1753114800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"American depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease.The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year.The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDHL":"Redhill Biopharma Ltd","BK4007":"制药"},"translate_title":"FDA对克罗恩病药物给予积极反馈后，RedHill Biopharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDHL":0.9},"content_text":"By Nicholas G. Miller\n\n\n \n\n\nAmerican depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease. \n\n\n  The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year. \n\n\n  The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 21, 2025 12:20 ET (16:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}